+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Chronic Fatigue Syndrome Treatment Market Report and Forecast 2023-2031

  • PDF Icon

    Report

  • 160 Pages
  • April 2023
  • Region: Global
  • Expert Market Research
  • ID: 5780620
The global chronic fatigue syndrome treatment market size was valued at USD 47.2 million in 2022 and is projected to grow at a CAGR of 4.2% during the forecast period of 2023-2031 to reach a value of USD 68.2 million by 2031. The market growth can be attributed to the increasing prevalence of chronic fatigue syndrome and the rising awareness about the condition.

Global Chronic Fatigue Syndrome Treatment Market: Introduction

Chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME), is a complex disorder characterized by extreme fatigue that cannot be explained by any underlying medical condition. The fatigue is worsened by physical or mental activity and does not improve with rest. Treatment options for CFS include medication, counselling, and lifestyle changes to manage symptoms and improve the quality of life for patients. The increasing prevalence of CFS, rising awareness about the condition, and the growing demand for effective treatment options are driving the market growth.

Advancements in diagnostic tools and treatment approaches have played a significant role in the growth of the chronic fatigue syndrome treatment market. The development of telemedicine and online therapy platforms has made CFS treatment more accessible to people who may have difficulty accessing traditional in-person care. This has expanded the reach of CFS treatment and helped to meet the growing demand for services.

The chronic fatigue syndrome treatment market is expected to continue to grow in the coming years, as awareness of the condition continues to increase, and new treatment options and technologies are developed to meet the needs of patients with CFS. However, there are still significant barriers to accessing CFS treatment, particularly in low- and middle-income countries, where access to healthcare services is often limited. Efforts are underway to address these barriers and improve access to CFS treatment globally.

Epidemiology of Chronic Fatigue Syndrome

Chronic fatigue syndrome affects millions of people worldwide, with varying prevalence rates reported across different countries and regions. According to the Centers for Disease Control and Prevention (CDC), an estimated 836,000 to 2.5 million Americans suffer from CFS but majority of them remain undiagnosed. In Europe, the estimated prevalence of CFS ranges from 0.4% to 2.5% of the population. In Asia, the prevalence of CFS is reported to be lower, ranging from 0.2% to 1.2%.

It affects both genders, but it is more prevalent among women than men. Women are reported to be two to four times more likely to develop CFS than men. The condition can affect individuals of all ages, but it is most diagnosed in people between the ages of 40 and 60. Chronic fatigue syndrome can also affect children and adolescents, but it is less common in these age groups.

Chronic Fatigue Syndrome Treatment Market Segmentations

The market can be segmented based on types, modes, distribution channels, end user, and major regions:

Market Breakup by Type

  • Immune Enhancer and Antivirals
  • Sleep Enhancer
  • CNS Stimulants
  • Others

Market Breakup by Mode

  • Prescription Drugs
  • OTC Drugs

Market Breakup by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Market Breakup by End User

  • Hospitals
  • Clinics
  • Research Laboratories

Market Breakup by Region

North America

  • United States of America
  • Canada

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Chronic Fatigue Syndrome Treatment Market Analysis

The market has experienced significant growth over the past few years, driven by factors such as the increasing prevalence of CFS, rising awareness about the condition, and the growing demand for effective treatment options. Another key driver of the market growth is the increasing prevalence of CFS.

North America is currently the largest market for chronic fatigue syndrome treatment, accounting for a significant share of the global market. The region's large market share is driven by factors such as a high prevalence of CFS, a well-established healthcare infrastructure, and strong investment in CFS research and development. In addition, the growing adoption of digital CFS treatment technologies, such as telemedicine and online therapy, is further driving the growth of the market in North America.

Asia Pacific is another region that is experiencing significant growth in the chronic fatigue syndrome treatment market. The region's market growth is driven by factors such as a large population base, increasing awareness of CFS, and the growing adoption of digital CFS treatment technologies. In addition, government initiatives to address CFS are helping to drive the growth of the market in the region.

Key Players in the Global Chronic Fatigue Syndrome Treatment Market

The report provides a detailed analysis of the key players involved in the chronic fatigue syndrome treatment market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:
  • Hemispherx Biopharma
  • GP Pharm
  • Cadila Pharmaceuticals
  • USV
  • Torrent Labs
  • Goodfellow Pharma
  • F. Hoffmann-La Roche Ltd

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Chronic Fatigue Syndrome Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Chronic Fatigue Syndrome Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Chronic Fatigue Syndrome Epidemiology (2016-2031)
5.3 Europe Chronic Fatigue Syndrome Epidemiology (2016-2031)
5.4 Asia-Pacific Chronic Fatigue Syndrome Epidemiology (2016-2031)
5.5 Latin America Chronic Fatigue Syndrome Epidemiology (2016-2031)
5.6 Middle East & Africa Chronic Fatigue Syndrome Epidemiology (2016-2031)
6 Global Chronic Fatigue Syndrome Treatment Market Overview
6.1 Global Chronic Fatigue Syndrome Treatment Market Historical Value (2016-2022)
6.2 Global Chronic Fatigue Syndrome Treatment Market Forecast Value (2023-2031)
7 Global Chronic Fatigue Syndrome Treatment Market Landscape
7.1 Chronic Fatigue Syndrome Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Chronic Fatigue Syndrome Treatment: Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Mode
7.2.3 Analysis by Distribution Channel
7.2.4 Analysis by End User
8 Chronic Fatigue Syndrome Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Chronic Fatigue Syndrome Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Chronic Fatigue Syndrome Treatment Market Segmentation
11.1 Global Chronic Fatigue Syndrome Treatment Market by Type
11.1.1 Market Overview
11.1.2 Immune Enhancer and Antivirals
11.1.3 Sleep Enhancer
11.1.4 CNS Stimulants
11.1.5 Others
11.2 Global Chronic Fatigue Syndrome Treatment Market by Mode
11.2.1 Market Overview
11.2.2 Prescription Drugs
11.2.3 OTC Drugs
11.3 Global Chronic Fatigue Syndrome Treatment Market by Distribution Channel
11.3.1 Market Overview
11.3.2 Hospital Pharmacies
11.3.3 Retail Pharmacies
11.3.4 Online Pharmacies
11.4 Global Chronic Fatigue Syndrome Treatment Market by End User
11.4.1 Market Overview
11.4.2 Hospitals
11.4.3 Clinics
11.4.4 Research Laboratories
11.5 Global Chronic Fatigue Syndrome Treatment Market by Region
11.5.1 Market Overview
11.5.2 North America
11.5.3 Europe
11.5.4 Asia Pacific
11.5.5 Latin America
11.5.6 Middle East and Africa
12 North America Chronic Fatigue Syndrome Treatment Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Chronic Fatigue Syndrome Treatment Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Chronic Fatigue Syndrome Treatment Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Chronic Fatigue Syndrome Treatment Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Chronic Fatigue Syndrome Treatment Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Hemispherx Biopharma
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 GP Pharm
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Cadila Pharmaceuticals
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 USV
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Torrent Labs
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Goodfellow Pharma
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 F. Hoffmann-La Roche Ltd
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
24 Chronic Fatigue Syndrome Treatment - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Companies Mentioned

  • Hemispherx Biopharma
  • GP Pharm
  • Cadila Pharmaceuticals
  • USV
  • Torrent Labs
  • Goodfellow Pharma
  • F. Hoffmann-La Roche Ltd

Methodology

Loading
LOADING...

Table Information